Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
Target Indication
Head and Neck Squamous Cell Carcinoma (HNSCC)
Clinical Trial
NCT06295731Last updated: 12/4/2025
INBX
Inhibrx Biosciences, Inc.